|
A targeted literature review provides a rapid collation of published literature evidence to support DTC decision making. It does not provide a critical evaluation of the literature, nor does it make recommendations about place in therapy of the medicine in question. However, it can be produced much more quickly than a Position Statement, and is therefore of value to DTCs in managing formulary decisions.
Antiplatelet Therapies: Current Issues (November 2009)
Adalimumab in inflammatory bowel disorders (March 2008)
Infliximab in Ulcerative Colitis (August 2007)
Drugs for the treatment of secondary hyperparathyroidism and hyperphosphataemia (June 2007)
Infliximab in Crohn's Disease (April 2007)
|
